• 1
    Okuda K and the Liver Cancer Group of Japan. Primary liver cancer in Japan. Cancer 1980; 45: 2663-9.
  • 2
    Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res 1968; 28: 1344-50.
  • 3
    O'Conor GI, Tatarinov YS, Abelev GI, Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 1970; 25: 1091-8.
  • 4
    Nishi S, Hirai H. Radioimmunoassay of alpha-fetoprotein in hepatoma, other liver diseases and pregnancy. Gann Monogr 1973; 14: 79-87.
  • 5
    Liebman H, Furie BC, Tong MJ, Blanchard RA, Lo K-J, Lee S-D, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-31.
  • 6
    Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma: a clinical and experimental study. J Hepatol 1987; 4: 357-63.
  • 7
    Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988; 61: 1621-8.
  • 8
    Hattori N, Ohmizo R, Unoura M, Tanaka N, Kobayashi K, and the PIVKA-II collaborative working group. Abnormal prothrombin measurements in hepatocellular carcinoma. J Tumor Marker Oncol 1988; 3: 207-16.
  • 9
    Yumoto Y, Jinno K, Tokuyama K, Ishimitsu T, Maeda H, Konno T, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985; 154: 19-24.
  • 10
    Schwerk WB, Schmitz-Moormann P. Ultrasonically guided fine-needle biopsies in neoplastic liver diseases: cytohistologic diagnosis and echo pattern of lesions. Cancer 1981; 48: 1469-77.
  • 11
    Noguchi S, Yamamoto R, Tatsuta M, Kasugai H, Okuda S, Wada A, et al. Cell features and patterns in fine-needle aspirate of hepatocellular carcinoma. Cancer 1986; 58: 321-8.
  • 12
    Majima Y, Fujimoto T, Iwai I, Tanaka M, Abe M, Abe H, et al. Histological diagnosis of hepatocellular carcinoma by a new technique of ultrasound-guided fine-needle biopsy [in Japanese]. Acta Hepatol Jpn 1988; 29: 628-36.
  • 13
    Shinagawa T, Ohto M, Kimura K, Tsunetomi S, Morita M, Saisho H, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography: a study in 51 patients. Gastroenterology 1984; 86: 495-502.
  • 14
    Karvountzis GG, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Intern Med 1974; 80: 156-60.
  • 15
    Chen D-S, Sung J-L. Serum alpha-fetoprotein in hepatocellular carcinoma. Cancer 1977; 40: 779-83.
  • 16
    Alpert E, Feller ER. Alpha-fetoprotein (AFP) in benign liver diseases: evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 1978; 74: 856-8.
  • 17
    Aoyagi Y, Suzuki Y, Isemura M, Soga K, Ozaki T, Ichida T, et al. Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gann 1984; 75: 809-15.
  • 18
    Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988; 61: 769-74.
  • 19
    Aoyagi Y, Isemura M, Suzuki Y, Sekine C, Soga K, Ozaki T, et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 1985; ii: 1353-4.
  • 20
    Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990; 99: 508-18.
  • 21
    Aoyagi Y, Isemura M, Yosizawa Z, Suzuki Y, Sekine C, Ono T, et al. Fucosylation of serum alpha-fetoprotein with primary hepatocellular carcinoma. Biochim Biophys Acta 1985; 830: 217-.
  • 22
    Aoyagi Y, Suzuki Y, Igarashi K, Saitoh A, Oguro M, Yokota T, et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer 1993; 67: 486-92.
  • 23
    Watanabe K, Naraki T, Yokoo T, Yamane S, Saitoh S, Okuda H, et al. Development of sensitive enzyme-immunoassay kit of PIVKA-II (ED 036) [in Japanese]. Rinshou to Kenkyu 1996; 73: 1476-81.
  • 24
    Takatsu K, Nakanishi T, Watanabe K, Okuda H, Hayashi N. Development of sensitive enzyme-immunoassay kit of PIVKA-II (ED 036). 2nd report. Evaluation of diagnostic ability. Rinshou to Kenkyu 1997; 74: 2137-41.
  • 25
    Saitoh S, Ikeda K, Koida I, Tsubota A, Arase Y, Chayama K, et al. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas. Cancer 1994; 74: 2918-23.
  • 26
    Soga K, Arai F, Tsuruya T, Aikawa K, Toshima M, Shibasaki K, et al. Studies on factors affecting plasma PIVKA-II levels in hepatocellular carcinoma. Acta Med Biologica 1993; 41: 197-200.